Evaluation of bone turnover after bisphosphonate withdrawal and its influence on implant osseointegration: an in vivo study in rats

Imagem de Miniatura
Arquivos
art_FRIZZERA_Evaluation_of_bone_turnover_after_bisphosphonate_withdrawal_and_2019.PDF (1.77 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
FRIZZERA, Fausto
VERZOLA, Mario Henrique Arruda
MOLON, Rafael Scaf de
OLIVEIRA, Guilherme Jose Pimentel Lopes de
GIRO, Gabriela
SPOLIDORIO, Luis Carlos
TETRADIS, Sotirios
CIRELLI, Joni Augusto
ORRICO, Silvana Regina Peres
Autor de Grupo de pesquisa
Citação
CLINICAL ORAL INVESTIGATIONS, v.23, n.4, p.1733-1744, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectivesThe aim of this study was to investigate bone turnover alterations after alendronate (ALD) withdrawal and its influence on dental implants osseointegration.Materials and methodsSeventy female Wistar rats were randomly divided in 2 groups that received on day 0 either placebo (control groupCTL; n=10) or 1mg/kg sodium alendronate (ALD; n=60) once a week for 4months. At day 120, ALD treatment was suspended for 50 animals. Then, a titanium implant was placed in the left tibia of each rat that were randomly allocated in five subgroups of ten animals each, according to the period of evaluation: day 0 (INT-0), day 7 (INT-7), day 14 (INT-14), day 28 (INT-28), and day 45 (INT-45) after ALD withdrawal. CTL group and a group that received ALD until the end of the experimental period (non-interrupted groupnon-INT; n=10) underwent implant placement on day 120. Animals were euthanized 28days after implant surgery. Bone mineral density (BMD) of femur and lumbar vertebrae were evaluated by DXA, biochemical markers of bone turnover were analyzed by ELISA, and bone histomorphometry was performed to measure bone-to-implant contact (BIC) and bone area fraction occupancy (BAFO).ResultsAll groups receiving ALD showed higher BMD values when compared to CTL group, which were maintained after its withdrawal. Decreased concentrations in all bone turnover markers were observed in the non-INT group, and in the groups in which ALD was discontinued compared to the CTL group. The non-INT group showed lower %BIC and notably changes in bone quality, which was persistent after drug withdrawal.ConclusionCollectively, the findings of this study demonstrated that ALD therapy decreased bone turnover and impaired bone quality and quantity around dental implants, and that its discontinuation did not reverse these findings.Clinical relevanceThe severe suppression of bone turnover caused by the prolonged use of ALD may alter the capacity of bone tissue to integrate with the implant threads impairing the osseointegration process.
Palavras-chave
Bisphosphonate, Alendronate, Rats, Osteoclasts, Dental implants, Osseointegration
URI
https://observatorio.fm.usp.br/handle/OPI/31599
Referências
  1. Abraham A, 2013, CLIN OBSTET GYNECOL, V56, P722, DOI 10.1097/GRF.0b013e3182a8ae55
  2. Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
  3. Bagger YZ, 2003, BONE, V33, P301, DOI 10.1016/S8756-3282(03)00112-1
  4. Bedogni A, 2010, J ORAL MAXIL SURG, V68, P1662, DOI 10.1016/j.joms.2010.02.037
  5. Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600-0501.2003.00972.x
  6. Black DM, 2015, J BONE MINER RES, V30, P934, DOI 10.1002/jbmr.2442
  7. Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
  8. Black DM, 2006, JAMA-J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
  9. Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
  10. Carvalho MD, 2006, J PERIODONTOL, V77, P599, DOI 10.1902/jop.2006.050190
  11. Chacon GE, 2006, J ORAL MAXIL SURG, V64, P1005, DOI 10.1016/j.joms.2006.01.007
  12. Chen JT, 1996, J BONE MINER RES, V11, P1784
  13. da Silva AG, 2011, ARQ BRAS ENDOCRINOL, V55, P272, DOI 10.1590/S0004-27302011000400006
  14. de Molon RS, 2016, J BONE MINER RES, V31, P1596, DOI 10.1002/jbmr.2827
  15. de Molon RS, 2015, J BONE MINER RES, V30, P1627, DOI 10.1002/jbmr.2490
  16. de Molon RS, 2014, BONE, V68, P11, DOI 10.1016/j.bone.2014.07.027
  17. de Molon RS, 2013, CLIN ORAL IMPLAN RES, V24, P831, DOI 10.1111/j.1600-0501.2012.02467.x
  18. dos Santos PL, 2016, J PERIODONTAL IMPLAN, V46, P176, DOI 10.5051/jpis.2016.46.3.176
  19. Duarte PM, 2005, J PERIODONTOL, V76, P107, DOI 10.1902/jop.2005.76.1.107
  20. Duarte Poliana Mendes, 2003, Implant Dent, V12, P340
  21. Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
  22. Fuchs RK, 2008, J BONE MINER RES, V23, P1689, DOI 10.1359/JBMR.080501
  23. Giro G, 2008, ORAL SURG ORAL MED O, V105, P162, DOI 10.1016/j.tripleo.2007.06.010
  24. Giro G, 2007, J PERIODONTOL, V78, P1316, DOI 10.1902/jop.2007.060390
  25. Giro G, 2011, CLIN ORAL IMPLAN RES, V22, P259, DOI 10.1111/j.1600-0501.2010.01989.x
  26. Grey A, 2010, J BONE MINER RES, V25, P2251, DOI 10.1002/jbmr.103
  27. Guimaraes MB, 2015, INT J ORAL MAX SURG, V44, P1423, DOI 10.1016/j.ijom.2015.05.013
  28. Manzano-Moreno FJ, 2015, CLIN ORAL INVEST, V19, P895, DOI 10.1007/s00784-014-1309-z
  29. Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010
  30. Kim YJ, 2018, INT J ORAL MAX IMPL, V33, P512, DOI 10.11607/jomi.5959
  31. Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
  32. Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
  33. Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
  34. Mardas N, 2011, CLIN ORAL IMPLAN RES, V22, P406, DOI 10.1111/j.1600-0501.2010.02094.x
  35. Narai S, 2003, INT J ORAL MAX IMPL, V18, P218
  36. Nociti FH, 2002, INT J ORAL MAX IMPL, V17, P786
  37. Pan JL, 2000, J ORAL MAXIL SURG, V58, P877, DOI 10.1053/joms.2000.8212
  38. Queiroz TP, 2017, CLIN ORAL INVEST, V21, P685, DOI 10.1007/s00784-016-1936-7
  39. Russell G, 2001, Novartis Found Symp, V232, P251
  40. Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198-007-0540-8
  41. Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
  42. Shahnazari M, 2011, J BONE MINER RES, V26, P569, DOI 10.1002/jbmr.249
  43. Shirota T, 2003, J ORAL MAXIL SURG, V61, P471, DOI 10.1053/joms.2003.50093
  44. Soundia A, 2016, BONE, V90, P133, DOI 10.1016/j.bone.2016.06.011
  45. Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
  46. Tamura Y, 2001, J BONE MINER RES, V16, P541, DOI 10.1359/jbmr.2001.16.3.541
  47. Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
  48. Tokugawa Y, 2003, INT J ORAL MAX IMPL, V18, P66
  49. Tolia M, 2014, ANTICANCER RES, V34, P23
  50. Verzola MHA, 2015, CLIN ORAL IMPLAN RES, V26, P1466, DOI 10.1111/clr.12492
  51. Vidigal G M Jr, 1999, Implant Dent, V8, P295, DOI 10.1097/00008505-199903000-00015
  52. Viera-Negron Yeritxa E, 2008, J Oral Implantol, V34, P76, DOI 10.1563/1548-1336(2008)34[76:EOOAAO]2.0.CO;2
  53. Vohra F, 2014, ARCH ORAL BIOL, V59, P912, DOI 10.1016/j.archoralbio.2014.05.016
  54. Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
  55. Wasnich Richard D, 2004, Menopause, V11, P622
  56. Wolf G, 1996, NUTR REV, V54, P332
  57. Yamazaki M, 1999, ORAL SURG ORAL MED O, V87, P411, DOI 10.1016/S1079-2104(99)70239-8
  58. Yildiz A, 2010, J ORAL MAXIL SURG, V68, P515, DOI 10.1016/j.joms.2009.07.066
  59. Yip JK, 2012, J CLIN PERIODONTOL, V39, P408, DOI 10.1111/j.1600-051X.2012.01854.x
  60. Yuan K, 2012, IMPLANT DENT, V21, P3, DOI 10.1097/ID.0b013e3182425c62
  61. Zagury R, 2007, IMPLANT DENT, V16, P290, DOI 10.1097/ID.0b013e3180e9d9ed

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17